RxDoctor Payments Data

Alex Lazar, MD

Psychiatry · Encino, CANPI 1154377315

Payments from drug & device makers

$11,623in general payments, 2019–2025

Across 478 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lundbeck LLC$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$953
  • Takeda Pharmaceuticals U.S.A., Inc.$935
  • Supernus Pharmaceuticals, Inc.$770
  • plus $4K from 24 others

What the payments were for

  • Food & beverage$11,620100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,623 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$56,191
Medicare patients
53
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant12$5,058
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine17$3,713
Chlorpromazine Hcl12$2,340
Aripiprazole33$1,934
Bupropion XlBupropion Hcl62$1,865
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$1,763
Escitalopram Oxalate41$1,723
Quetiapine Fumarate43$1,626
Olanzapine50$1,086
Trazodone Hcl64$1,069
Mirtazapine52$1,023
Lorazepam46$858
Fluoxetine Hcl33$626
Lurasidone Hcl16$561
Venlafaxine Hcl ErVenlafaxine Hcl14$546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$31$26823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →